Department of Psychiatry, The Seventh People's Hospital of Hangzhou (Affiliated Mental Health Center, Zhejiang University School of Medicine), Hangzhou, Zhejiang Province, China
Auto-generated profile, based on publicly available information
Xiwen Hu
Department of Psychiatry, The Seventh People's Hospital of Hangzhou (Affiliated Mental Health Center, Zhejiang University School of Medicine), Hangzhou, Zhejiang Province, China
Medial prefrontal cortex (MPFC) and other regions like the occipital cortex (OC) exhibit abnormal neural activity in major depressive disorder (MDD). Their relationship to specific biochemical, psychophysical, and psychopathological changes remains unclear, though. For that purpose, we focus on a particular subregion in OC, namely middle temporal (MT) visual area that is known to mediate the perception of visual motion. Using high-field 7 T magnetic resonance imaging (MRI), including resting state functional MRI and proton magnetic resonance spectroscopy, the amplitude of low-frequency fluctuations (ALFF) of the blood oxygen level-dependent signal in MT, MT-seeded functional connectivity (FC), and gamma-aminobutyric acid (GABA) in MT were investigated. Applying the vision motion psychophysical task, the motion suppression index of subjects was also examined. We demonstrate significantly elevated neural variability (as measured by ALFF) in MT together with decreases in both MT GABA and motion suppression in our MDD sample. Unlike in healthy subjects, MT neural variability no longer modulates the relationship of MT GABA and motion suppression in MDD. MT also exhibits reduction in global inter-regional FC to MPFC in MDD. Finally, elevated MT ALFF relates to specifically retardation in behavior as measured by the Hamilton subscore. Together, MT provides a strong candidate for biomarker in MDD.
We aimed to investigate the differential diagnosis of depressive episodes in patients with major depressive disorder (MDD) and bipolar disorder (BD) using peripheral blood cytokine expression levels. The levels of interleukin (IL)-2, IL-6, IL-10, IL-17, IL4, and IL-12; interferon (IFN)-γ; and tumor necrosis factor (TNF)-α were measured in patients with MDD and BD presenting acute episodes in an inpatient psychiatric setting. The expression levels of IL-6, IL-10, IL-17, and IFN-γ in the MDD and BD groups were higher than those in the control group (P < .05), but there was no significant difference between the patient groups and control group. Only the expression levels of TNF-α and IL-4 were higher in both groups than in the control group, and the BD group had higher levels than the MDD group (P < .05). The expression levels of IL-17, IFN-γ, IL-10, and IL-4 were significantly higher in BD-related manic episodes than in BD-related depressive episodes (P < .05). IL-6, IFN-γ, TNF-α, IL-10, and IL-4 levels were higher in BD-related depressive episodes than in MDD-related depressive episodes (P < .05). The receiver operating characteristic curve test for MDD and BD and the area under the curve for IL-4 revealed good clinical predictability. Patients with MDD and BD exhibited different cytokine profiles when experiencing acute episodes; patients with BD exhibited a more severe immune-inflammatory response system–compensatory immunoregulatory response system (CIRS) imbalance. IL-4 was found to have diagnostic value in differentiating between active depressive episodes in MDD and BD.
Background. To date, around 4 per 100,000 adolescents committed suicide within the 29 OECD countries. The suicidal behavior is related to psychological factors, genetics, neurobiology, and other biomarkers. The aim of this study was to examine risk factors for the development of suicidal ideation in adolescent females with depression, focusing on the relationship between different testosterone levels and suicidal ideation, in order to help develop strategies to intervene in suicidal behavior in female adolescents with depression. Method. In this single-center prospective cohort study, we enrolled adolescent females with depression. We collected information on their baseline data, testosterone levels, symptom self-rating scale scores, suicidal ideation, non-suicidal self-injurious (NSSI) behaviours, and suicide attempts. We used multivariate logistic regression to identify risk factors for the development of suicidal ideation in adolescent females with depression. Results. A total of 113 hospitalized adolescent females were enrolled with a mean age of 13.5 (1.20). Among these patients, there were 86 (76.11%) subjects who suffered from suicidal ideation, 59 (52.21%) had NSSI and 23 (20.35%) had suicide attempt behavior. In the final model, higher level of testosterone ( ) and higher age ( ) were associated with the higher odds of having suicidal ideation. Conclusion. In this exploratory cohort study, the emergence of suicidal ideation was common among adolescent females with depression. This study is consistent with the other studies. It shows that the age is a potential predictor for suicidal ideation in hospitalized adolescent females with depression.
To establish a pharmacokinetic model-based method for converting random concentrations of quetiapine (QTP) and its active metabolite N-desmethylquetiapine (N-QTP) to steady-state trough concentrations, and validate its component-specific accuracy using paired patient data to address the clinical challenge of interpreting non-standard time samples in therapeutic drug monitoring (TDM). Core pharmacokinetic parameters (QTP half-life: 7 h; N-QTP half-life: 12 h) were confirmed via systematic literature review. Phase-specific conversion formulas were derived based on first-order kinetic decay, with 14 h post-dose as the standard trough time (midpoint of 12-16 h guideline window). A longitudinal validation cohort of 80 schizophrenia patients (steady-state QTP administration ≥7 days) was enrolled: each patient underwent two blood samplings on separate dosing days (1 random time point [2-26 h] and 1 standard 14 h trough sampling). Python was used to calculate conversion coefficients (1-48 h), and accuracy was validated by comparing QTP-specific, N-QTP-specific, and total estimated trough concentrations with concurrently measured trough concentrations (gold standard). Conversion coefficients for 1-48 h were generated. Validation with paired data (n = 80) showed strong component-specific and overall agreement: For QTP alone, Pearson correlation coefficient (r) = 0.89 (P < 0.001), mean relative error (RE) = 10.1 % ± 4.2 % (range: 5.3 %-15.8 %), and 82.5 % of estimates with RE < 15 %; for N-QTP alone, r = 0.91 (P < 0.001), mean RE = 7.8 % ± 3.1 % (range: 3.2 %-13.2 %), and 93.8 % of estimates with RE < 15 %; for total concentration (QTP + N-QTP), r = 0.92 (P < 0.001), mean bias = -5.2 ng/mL (95 % CI: -11.7-1.3), limits of agreement (LOA) = -34.8-24.4 ng/mL, mean RE = 9.2 % ± 3.7 % (range: 4.8 %-14.5 %), and 87.5 % of estimates with RE < 15 %. Stratified analysis by sampling time point confirmed consistent accuracy across 2-26 h, with optimal performance at 6-10 h (RE < 9 %). The conversion method, rigorously validated for both QTP and N-QTP with paired patient data, demonstrates robust component-specific and overall accuracy for clinical use. It provides a practical, eadily applicable lookup table to facilitate TDM interpretation when standard trough sampling is unfeasible, thereby supporting personalized quetiapine therapy for schizophrenia and bipolar disorder.